The NHS AI commission has given healthcare regulation its own support group, because artificial intelligence could not possibly enter the NHS until several eminent people had introduced themselves around a circular table.
The Medicines and Healthcare products Regulatory Agency has created a National Commission on AI in Healthcare to advise on a new regulatory rulebook. It brings together clinicians, patient advocates, researchers, regulators and technology companies. This breadth matters. It also means the first tool to receive safe access may be a meeting scheduler with a doctorate in finding the only date nobody can attend.
The commission will review AI tools held up by regulatory uncertainty, including assistants that help doctors take notes. It will also consider systems used in radiology, pathology and remote monitoring. The technology may eventually save clinicians time, but first a roomful of humans must spend several months explaining the word “safe” to one another in increasingly careful language.
“Innovation needs clarity,” said Matilda Byte, Secretary for Carefully Managed Tomorrow. “So we are writing a clear rulebook, then establishing a working group to make sure the clarity has not become too clear.”
The rulebook is planned for 2026. In the meantime, the commission can advise on technology already waiting for regulatory certainty. That is sensible, particularly in healthcare, where badly governed software can do more than produce a disappointing spreadsheet. Still, every national commission risks becoming a ceremonial hat rack for urgent ideas.
Here is the contradiction. The government wants the NHS to adopt AI quickly, attract technology investment and become a world leader in responsible healthcare technology. It also wants every risk considered, every voice heard and every framework robust enough to survive contact with a committee. The result is an institution designed to make innovation move at the speed of caution while describing that speed as acceleration.
Safety and public confidence matter. So does giving clinicians tools that reduce administrative work rather than adding another form about the form they have just completed. The commission’s first meeting reportedly ended with the rulebook asking whether it had consented to being innovative. The minutes recorded a cautious maybe, pending a subgroup. The subgroup then requested a review of whether the word “maybe” had been safely deployed.
Source: Medicines and Healthcare products Regulatory Agency.
